GlassScriptPhysician profile
Daniela O Tapos
NPI 1770755936
$2,509.20
in general payments reported to CMS, 2019-2025
16 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $184 · 2021: $48.07 · 2022: $204 · 2023: $330 · 2024: $1,026 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $396.15 | 2023-2024 | Briviact, Fintepla, Nayzilam |
| Livanova USA, INC. | $343.67 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $212.93 | 2019-2023 | |
| Neurelis, INC. | $210.74 | 2021-2025 | Valtoco |
| Aquestive Therapeutics, INC. | $184.33 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $180.90 | 2023-2025 | Epidiolex |
| Neuropace, INC. | $153.83 | 2024 | |
| Greenwich Biosciences, INC. | $145.62 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $138.04 | 2024 | |
| Ptc Therapeutics, INC. | $137.67 | 2023 | Emflaza |
| Sunovion Pharmaceuticals INC. | $122.19 | 2019 | |
| Pyros Pharmaceuticals, INC. | $107.96 | 2024 | Vigpoder |
| Mallinckrodt Enterprises LLC | $105.94 | 2019 | |
| Genzyme Corporation | $35.67 | 2024 | |
| Supernus Pharmaceuticals, INC. | $17.31 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $16.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Tapos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.